Protara Therapeutics, Inc. (TARA) — Analyst outlook / Analyst consensus target is. Based on 5 analyst ratings, the consensus is bullish — 5 Buy.
The consensus price target is $12.00, representing an upside of 133.9% from the current price $5.13.
Analysts estimate Earnings Per Share (EPS) of $-2.20 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-2.17 vs est $-2.20 (beat +1.4%). 2025: actual $-1.34 vs est $-1.26 (missed -6.2%). Analyst accuracy: 96%.
TARA Stock — 12-Month Price Forecast
$12.00
▲ +133.92% Upside
Average Price Target
Based on 5 Wall Street analysts offering 12-month price targets for Protara Therapeutics, Inc., the price target is $12.00.
The average price target represents a +133.92% change from the last price of $5.13.
TARA Analyst Ratings
Buy
Based on 5 analysts giving stock ratings to Protara Therapeutics, Inc. in the past 3 months
EPS Estimates — TARA
96%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$2.17
vs Est –$2.20
▲ 1.4% off
2025
Actual –$1.34
vs Est –$1.26
▼ 5.9% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — TARA
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
